Florian Rader, ACC 2022: Interim results of the MAVA-LTE study of mavacamten in the treatment of symptomatic obstructive hypertrophic cardiomyopathy
In the MAVA-LTE and EXPLORER LTE studies, mavacamten is predicted to reduce left ventricular outflow tract obstruction and potentially reduce heart thickening in patients with symptomatic obstructive hypertrophic cardiomyopathy. touchCARDIO spoke to Dr Florian Rader (Cedars-Sinai Medical Center, Los Angeles, CA, USA) to discusses the interim results of the MAVA-LTE study and the clinical implications of the results of the EXPLORER LTE study.
The presentation entitled: ‘Updated Cumulative Results of Treatment With Mavacamten From the EXPLORER-LTE Cohort of the MAVA-LTE Study in Patients With Obstructive Hypertrophic Cardiomyopathy’ was presented at the the American College of Cardiology Annual Meeting 2022.
- What is the mechanism of action of mavacamten and what is the rationale for its use in obstructive hypertrophic cardiomyopathy? 00:15-01:58
- What are the aims and design of the MAVA-LTE study? 01:58-03:16
- What have been the overall findings of the study to date? 03:16-06:36
- Could you tell us a little about the EXPLORER LTE study and the effect of mavacamten in this cohort? 06:46-07:48
- What are the clinical implications of these findings? 07:48-09:06
Speaker Disclosure: Florian Radar is a consultant for Medtronic, a member of the Advisory Board for Medtronic and ReCor and a Speaker’s Bureau participant for Medtronic and Bristol Myers Squibb.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
Share this Video
Related Videos In Cardiovascular Disease
John Forrest, ACC 2023: Evolut low risk trial, transcatheter versus surgical aortic valve replacement in patients at low surgical risk
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to discuss the eligibility criteria, the key findings and the outlook for […]
John Forrest, ACC 2023: The treatment paradigm for patients with aortic stenosis
The treatment paradigm for aortic stenosis has developed dramatically in the past decade. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to outline and discuss the developments. Dr Forrest presented an abstract entitled ‘Transcatheter Versus Surgical Aortic Valve Replacement In Aortic Stenosis Patients […]
Steven Nissen, ACC 2023: Lipid-lowering therapies – current and future options
Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to explore current and developing novel lipid-lowering […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!